Wetherby, United Kingdom

Avacta is a UK-based biopharmaceutical company developing novel cancer immunotherapeutics and high performing diagnostics, based on its two proprietary platforms: Affimer and pre|CISION.


Investment Perspective

Avacta is a UK-based diagnostic and nascent clinical stage drug development company. Much investor attention has focused on the near-term commercial opportunities for its point-of-care COVID-19 LFT (lateral flow test). Attractive as these prospects are, we argue greater long-term value lies within the Therapeutics pipeline. The first programme from the two proprietary platforms, Affimer and pre|CISION, is set to enter human trials. Successful clinical results would validate the concept and support a material broadening of the pipeline. Ample news flow is expected over 18-24 months, providing multiple value-inflection points. Our valuation is £710m, equivalent to 280p/share.

Market information

SymbolPrimary exchanges


Lead therapeutic asset AVA6000 enters the clinic
Lighthouse | 11 Aug 2021
So much more than a play on COVID testing
Initiation | 29 Jun 2021

Recent News

First patient dosed in AVA6000 Phase 1 trial
11 Aug 2021
Update on AffiDX Lateral Flow Test
04 Aug 2021
Diagnostics achieves ISO 13485 Certification
14 Jul 2021
AffiDX SARS-CoV-2 antigen LFT detects Delta variant
29 Jun 2021